Cidara Therapeutics (FRA:20D0) Total Stockholders Equity : €131.06 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Total Stockholders Equity?

Cidara Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was €131.06 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cidara Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was €10.73. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cidara Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.02.

Cidara Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Cidara Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Total Stockholders Equity Chart

Cidara Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

8.81

19.09

-13.63

-7.53

155.96

Cidara Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															-16.36	121.64	104.18	155.96	131.06

Cidara Therapeutics (FRA:20D0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cidara Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(131.056	-	0)	/	12.209
	=	10.73

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cidara Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.329	+	1.143)	/	131.056
	=	0.02

Cidara Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cidara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CDTX:USA 20D0:Germany

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121

Website

https://www.cidara.com

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Headlines

No Headlines